Utah Medical Products (UTMD)
(Delayed Data from NSDQ)
$65.92 USD
-0.37 (-0.56%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.92 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Utah Medical Products, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 50 | 52 | 49 | 42 | 47 |
Cost Of Goods | 20 | 20 | 18 | 17 | 17 |
Gross Profit | 30 | 32 | 31 | 26 | 29 |
Selling & Adminstrative & Depr. & Amort Expenses | 13 | 12 | 12 | 12 | 12 |
Income After Depreciation & Amortization | 17 | 20 | 19 | 14 | 18 |
Non-Operating Income | 3 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 20 | 21 | 19 | 14 | 18 |
Income Taxes | 3 | 4 | 4 | 3 | 3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 17 | 16 | 15 | 11 | 15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 17 | 16 | 15 | 11 | 15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 23 | 27 | 26 | 21 | 25 |
Depreciation & Amortization (Cash Flow) | 6 | 7 | 7 | 7 | 7 |
Income After Depreciation & Amortization | 17 | 20 | 19 | 14 | 18 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.64 | 3.64 | 3.66 | 3.67 | 3.74 |
Diluted EPS Before Non-Recurring Items | 4.57 | 4.52 | 4.15 | 3.00 | 3.78 |
Diluted Net EPS (GAAP) | 4.57 | 4.52 | 4.04 | 2.94 | 3.94 |
Fiscal Year end for Utah Medical Products, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 12.33 | 12.51 | 12.87 | 12.52 |
Cost Of Goods | NA | 5.24 | 5.15 | 5.13 | 4.68 |
Gross Profit | NA | 7.10 | 7.36 | 7.74 | 7.84 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.16 | 3.39 | 3.31 | 3.40 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.94 | 3.97 | 4.43 | 4.44 |
Non-Operating Income | NA | -1.96 | 0.81 | 0.75 | 0.68 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 5.02 | 4.78 | 5.17 | 5.12 |
Income Taxes | NA | 0.73 | 0.85 | 0.97 | 0.91 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 4.29 | 3.94 | 4.20 | 4.21 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 4.29 | 3.94 | 4.20 | 4.21 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 3.63 | 3.64 | 3.64 | 3.64 |
Diluted EPS Before Non-Recurring Items | NA | 1.18 | 1.08 | 1.15 | 1.16 |
Diluted Net EPS (GAAP) | NA | 1.18 | 1.08 | 1.15 | 1.16 |